EP1036069A1 - Composes benzenesulfamides - Google Patents

Composes benzenesulfamides

Info

Publication number
EP1036069A1
EP1036069A1 EP98962319A EP98962319A EP1036069A1 EP 1036069 A1 EP1036069 A1 EP 1036069A1 EP 98962319 A EP98962319 A EP 98962319A EP 98962319 A EP98962319 A EP 98962319A EP 1036069 A1 EP1036069 A1 EP 1036069A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
benzenesulfonamide
alkoxy
chloro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98962319A
Other languages
German (de)
English (en)
Inventor
Mario Varasi
Paolo Pevarello
Franco Heidempergher
Felicita Greco
Carmela Speciale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of EP1036069A1 publication Critical patent/EP1036069A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C07D263/50—Benzene-sulfonamido oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel benzenesulfonamides, to a process for their preparation, to pharmaceutical compositions containing them and their use in therapy.
  • the compounds of the invention act as inhibitors of kynurenine-3 -hydroxy lase (KYN- OH), an enzyme which forms part of the metabolic pathway of kynurenine. It is well known that through the kynurenine pathway, tryptophan metabolism gives rise to the formation of 3-hydroxy-kynurenine (3-OH-KYN) and quinolinic acid (QUIN), on the one side, and kynurenic acid (KYNA), on the other side, as shown in Figure 1.
  • KYNA is endowed with neuroprotective properties (J. Neurosci. 1990, 10, 2965-2973), whereas QUIN is a relatively potent neurotoxin which has been implicated in the pathogenesis of a variety of neurological disorders including Huntington's disease and epilepsy (Life Sci. 1984, 35, 19-32; Nature, 1986, 321, 168-171 ; Science, 1983, 219, 316-
  • X is O or S; at least one of R, R,, R 2 , R 3 , and R 4 , which are the same or different, is an unsaturated pentatomic heteromonocyclic ring containing one to three heteroatoms chosen independently from oxygen, sulphur and nitrogen, wherein the heteromonocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C,-C 6 alkyl, C r C 6 alkoxy, C 2 -C 6 alkanoylamino, formylamino and C,-C 6 alkoxy-carbonyl.
  • R 5 is hydrogen, C r C 6 alkyl, a benzyl or a phenyl group in which the phenyl moiety or the phenyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, trifluoromethyl, C r C 6 alkyl, C r C 6 alkoxy, nitro, amino, hydroxy, formylamino, C 2 -C 6 alkanoylamino and C r C 6 alkoxy-carbonyl; each of R 6 and R 7 , which are the same or different, is independently hydrogen or a phenyl ring unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C,-C 6 alkyl, C r C 6 alkoxy,
  • R, R., R 2 , R 3 , and R 4 which are the same or different, is an unsaturated pentatomic heteromonocyclic ring containing one to three heteroatoms chosen independently from oxygen, sulphur and nitrogen, wherein the heteromonocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C,-C 6 alkyl, C,-C 6 alkoxy, C 2 -C 6 alkanoylamino, formylamino and C r C 6 alkoxy-carbonyl.
  • R 5 is hydrogen, C r C 6 alkyl, a benzyl or a phenyl group in which the phenyl moiety or the phenyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, trifluoromethyl, C r C 6 alkyl, C r C 6 alkoxy, nitro, amino, hydroxy, formylamino, C 2 -C 6 alkanoylamino and C r C 6 alkoxy-carbonyl; each of R ⁇ and R 7 , which are the same or different, is independently hydrogen or a phenyl ring unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C r C 6 alkyl, C,-C 6 alkoxy, C
  • the present invention also provides a method of treating a mammal, including humans, in need of a kynurenine-3-hydroxylase enzyme inhibitor, the method comprising administering thereto a therapeutically effective amount of a benzenesulfonamide compound of formula (I) wherein X is O or S; at least one of R, R b R 2 , R 3 , and R 4 , which are the same or different, is an unsaturated pentatomic heteromonocyclic ring containing one to three heteroatoms chosen independently from oxygen, sulphur and nitrogen, wherein the heteromonocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C,-C 6 alkyl, C,-C 6 alkoxy, C 2 -C 6 alkanoylamino, formylamino and C r C 6 alkoxy-carbonyl. or two adjacent
  • R 5 is hydrogen, C,-C 6 alkyl, a benzyl or a phenyl group in which the phenyl moiety or the phenyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, trifluoromethyl, C,-C 6 alkyl, C,-C 6 alkoxy, nitro, amino, hydroxy, formylamino, C 2 -C 6 alkanoylamino and C r C 6 alkoxy-carbonyl; each of R 6 and R 7 , which are the same or different, is independently hydrogen or a phenyl ring unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C r C 6 alkyl, C,-C 6 alkoxy, C 2 -C 6 alkanoylamino, formylamino and C r C 6 alk
  • X is O or S; at least one of R, R,, R 2 , R 3 , .and R 4 , which .are the same or different, is an unsaturated pentatomic heteromonocyclic ring containing one to three heteroatoms chosen independently from oxygen, sulphur and nitrogen, wherein the heteromonocyclic ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C,-C 6 alkyl, C,-C 6 alkoxy. C 2 -C 6 alkanoylamino, formylamino and C r C 6 alkoxy-carbonyl.
  • R 5 is hydrogen, C r C 6 alkyl, a benzyl or a phenyl group in which the phenyl moiety or the phenyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, trifluoromethyl, C r C 6 alkyl, C r C 6 alkoxy, nitro, amino, hydroxy, formylamino, C 2 -C 6 alkanoylamino and C,-C 6 alkoxy-carbonyl; each of R 6 and R 7 , which are the same or different, is independently hydrogen or a phenyl ring unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C,-C 6 alkyl, C,-C 6 alkoxy,
  • the present invention includes within its scope all the possible isomers, stereoisomers, optical isomers and their mixtures and the metabolites and the metabolic precursors (or bioprecursors) of the compounds of formula (I).
  • Examples of pharmaceutically acceptable salts of the compounds of the invention are either those with inorganic bases, such as sodium, potassium hydroxydes as well as the salts with inorganic, e.g. hydrochloric, hydrobromic and sulphuric acids and with organic acids, e.g. citric, tartaric, maleic, malic, fumaric, methanesulfonic and ethanesulfonic acids.
  • inorganic bases such as sodium, potassium hydroxydes
  • organic acids e.g. citric, tartaric, maleic, malic, fumaric, methanesulfonic and ethanesulfonic acids.
  • the present invention also includes within its scope pharmaceutically acceptable bioprecursors (otherwise known as pro-drugs) of the compounds of formula
  • the alkyl, alkoxy, alkanoylamino and alkoxy-carbonyl groups may be branched or straight chain groups.
  • a C,-C 6 alkyl group is preferably a C,-C 4 alkyl group.
  • Representative examples of C r C 4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso-, sec-, and tert-butyl.
  • a C r C 6 alkoxy group is preferably a C r C 4 alkoxy group.
  • C 4 alkoxy groups include methoxy, and ethoxy.
  • a C 2 -C 6 alkanoylamino group is preferably an acetylamino or propionylamino group.
  • a C r C 6 alkoxy-carbonyl group is preferably a C C 4 alkoxy-carbonyl group typically a
  • a halogen is fluorine, bromine, chlorine or iodine, in particular chlorine, bromine or fluorine.
  • R-R 4 is a heteromonocyclic ring, said ring is linked to the phenyl moiety through a C-C bond and is preferably chosen from the group including pyrrole. furane, oxazole, isoxazole, thiazole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole,
  • R 6 and R 7 taken together for a C 6 -C, 4 aromatic ring system it is preferably phenyl or naphthyl.
  • Preferred compounds of formula (I) are those wherein:
  • X is O or S; at least one of R-R 4 is a heterocyclic ring selected independently from pyrrole, furane, oxazole, isoxazole, thiazole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, 1 ,2,4- oxadiazole, 1,3,4-thiadiazole, benzoxazole and benzothiazole in which said ring is optionally substituted by one or two substituents independently chosen from halogen,
  • R 5 is hydrogen, C,-C 4 alkyl, benzyl, or a phenyl ring, the phenyl ring being unsubstituted or substituted by one or two substituents chosen independently from halogen, trifluoromethyl, C r C 4 alkyl, C,-C 4 alkoxy, nitro, amino, hydroxy, formylamino, C 2 -C 4 alkanoylamino and C,-C 4 alkoxy-carbonyl; each of R 6 and R 7 which are the same or different, is independently hydrogen or phenyl wherein the phenyl ring is unsubstituted or substituted by one or two substituents chosen independently from halogen, hydroxy, trifluoromethyl, nitro, amino, phenyl, benzyl, C ⁇ - C 4 alkyl, C,-C 4 alkoxy, C 2 -C 4 alkanoyla
  • a compound of formula (I) may be converted into another compound of formula(I) by known methods.
  • a nitro group may be converted into an amino group by treatment, for example, with stannous chloride in concentrated hydrochloric acid using, an organic cosolvent such as dioxane, tetrahydrofuran at a temperature varying between room temperature and about 100 °C.
  • an organic cosolvent such as dioxane, tetrahydrofuran at a temperature varying between room temperature and about 100 °C.
  • an amino group may be converted into a formylamino or a C 2 - C 4 alkanoylamino group, for example by reacting with formic acid or with a suitable C 2 - C 4 alkanoyl anhydride without any solvent or in a organic solvent such as dioxane, dimethylformamide, tetrahydrofuran, usually in the presence of a base such as triethylamine, at a temperature varying between 0 °C and about 100 °C.
  • Y as leaving group is a good leaving group, for example a halogen atom, typically chlorine, iodine, or bromine, in particular chlorine.
  • the reaction between a compound of formula (II) and a compound of formula (III) can be carried out, for example, in the presence of a base such as triethylamine or pyridine, in a inert solvent such as toluene, dioxane, tetrahydrofuran, dimethylformamide, dichloromethane at a temperature varying between 0 °C and about 100 °C.
  • a base such as triethylamine or pyridine
  • a inert solvent such as toluene, dioxane, tetrahydrofuran, dimethylformamide, dichloromethane at a temperature varying between 0 °C and about 100 °C.
  • the reaction can be also carried out without base and solvent at a temperature varying between 100 °C and about 200 °C.
  • the conversion of a compound of formula (I) wherein R is hydrogen in another compound of formula (I) wherein R 5 is as defined above except hydrogen can be carried out, for example, in the presence of a base such as sodium hydride, potassium t-butoxide, potassium carbonate in a solvent such as 1 ,2-dimethoxyethane, dioxane, dimethylformamide, acetone and in the presence of a phase-transfer catalyst such as tetra- n-butylammonium iodide at a temperature ranging from about 0 °C to 100 °C, or in the presence of copper bronze and a base such as potassium carbonate at a temperature varying between 100 °C and about 200 °C.
  • a base such as sodium hydride, potassium t-butoxide, potassium carbonate in a solvent such as 1 ,2-dimethoxyethane, dioxane, dimethylformamide, acetone
  • a phase-transfer catalyst such as te
  • the intermediates of formula (II) are either described in Phosphorus, Sulfur, Silicon Relat. Elem. 92, 1-4, 1994, 65-76 or may be prepared analogously.
  • the intermediates of formula (III) are either commercially available or or can be obtained by known methods.
  • the compounds of the invention are active as kynurenine-3-hydroxylase enzyme inhibitors and therefore are useful in the prevention and/or treatment of neuropathological processes, related to a deranged production of quinolinic acid and/or 3- hydroxykynurenine due to excessive activation of neuro transmission mediated by excitatory amino acid receptors and/or oxidative stress.
  • neuropathological processes are neurodegenerative pathologies including, e.g.
  • Alzheimer's chorea Alzheimer's disease, Parkinson's disease, olivopontocerebellar atrophy, non- Alzheimer's dementias, including the dementia like syndrome caused by Acquired Immunodeficiency Syndrome (AIDS), multi-infarctual ' dementia, cerebral amyotrophic lateral sclerosis, cerebral ischemia, cerebral hypoxia, spinal and head trauma, and epilepsy.
  • AIDS Acquired Immunodeficiency Syndrome
  • multi-infarctual ' dementia cerebral amyotrophic lateral sclerosis
  • cerebral ischemia cerebral hypoxia
  • spinal and head trauma spinal and epilepsy.
  • a human or animal in need of a kynurenine-3 -hydroxy lase enzyme inhibitor can thus be treated by a method which comprises the administration thereto of a therapeutically effective amount of a compound of the invention or a salt thereof.
  • the condition of the human or animal can thereby be improved.
  • the efficacy of the compounds of the invention in the inhibition of the enzyme kynurenine-3 -hydroxy lase was evaluated e.g., in rat liver mitochondrial extract following the method reported below, according to the procedure described in "Analytical Biochem. (1992), 205, 257-262", with minor modifications.
  • the assay for kynurenine 3-hydroxylase is based on the enzymatic synthesis of tritiated water during the hydroxylation reaction. Radiolabeled water was quantified following selective adsorption of the isotopic substrate and its metabolite with activated charcoal. Rat liver mitochonidrial extract was used as enzymatic preparation for this assay.
  • the assay for kynurenine 3 -hydroxy lase activity was carired out at 37°C for a time of 30 min.
  • the reaction mixture of a total volume of 30 ⁇ l was constituted of 44 ⁇ g of suspended extract, 100 mM Tris/Cl " buffer pH 8.1 , 10 mM EDTA, 100 mM KC1, 0.8 mM NADPH, 0.025 mM L-Kynurenine, 0.3 ⁇ Ci L-(3,5- 3 H)Kynurenine (10 Ci/mmol) and 3 ⁇ l of different concentration of inhibitor solutions.
  • the reaction was terminated by the addition of 300 ⁇ l of 7.5% (W/v) activated charcoal, and centrifuged for
  • the dosage level suitable for administration to a mammal, e.g.: to humans, depends on the age, weight, conditions of the patient and on the administration route.
  • the oral dosage in adult humans for the compound 4-Benzoxazol-2-yl-N-(5- chloro-benzoxazol-2-yl)-benzenesulfonamide may range from about 10 to 500 mg pro dose from 1 to 5 times daily.
  • the compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous and/or intrathecal and/or intraspinal injection or infusion.
  • the invention includes also pharmaceutical compositions comprising a compound of the invention or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).
  • a pharmaceutically acceptable excipient which can be a carrier or a diluent.
  • compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
  • the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; desegregating agents, e.g.
  • diluents e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gum, gelatin, methylcellulose, carboxymethylcellulose or polyvin
  • a starch alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
  • Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
  • the liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscolar injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • the solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
  • carrier for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
  • the suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • a pharmaceutically acceptable carrier e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • Bromobenzene (0.72 g; 0.0046 mol), and 4-Benzoxazol-2-yl-N-(5-chloro-benzoxazol-2- yl)-benzenesulfonamide; (1.23 g; 0.0029 mol), copper bronze (0.45 g) and potassium carbonate (0J5 g) were heated at reflux for 10 h.
  • the cooled residue was ground with water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate and evaporated to dryness after filtration.
  • the mixture was stirred under nitrogen at 25 °C for 24 h.
  • N-Benzyl-N-Thiazol-2-yl-4-oxazol-2-yl-benzenesulfonamide N-Benzyl-N-[4-(2-Fluoro-5-trifluoromethyl-phenyl)-thiazol-2-yl]-4-isoxazol-3-yl- benzenesulfonamide;
  • Capsule each weighing 0.23 g and containing 50 mg of the active substance can be prepared as follow: Composition for 500 capsules:
  • This formulation can be encapsulated in two hard gelatin capsules of two pieces, each with each capsule weighing 0.23 g.
  • a pharmaceutical injectable composition can be manufactured dissolving 50 g of 4- Benzoxazol-2-yl-N-(5-chloro-benzoxazol-2-yl)-benzenesulfonamide in sterile propylenglycol (1000 mL) and sealed in 1-5 ampoules.
  • IDO Indolamineoxigenase
  • KYN Kynurenine
  • KYN-OH Kynurenine-3-hydroxylase
  • KYNA Kynurenic acid
  • 3-OHAA 3-Hydroxy anthranilic acid
  • KYNase Kynureninase
  • QUIN Quinolinic acid
  • KAT Kynurenine amino transferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention se rapporte à des composés représentés par la formule (I) dans laquelle X est O ou S; l'un au moins des groupes que sont R, R1, R2, R3 et R4, qui sont identiques ou différents, est un noyau hétéromonocyclique pentatomique comportant un à trois hétéroatomes sélectionnés indépendamment parmi l'oxygène, le soufre et l'azote, ledit noyau hétéromonocyclique étant non substitué ou substitué par un ou deux substituants sélectionnés indépendamment parmi halogène, hydroxy, trifluorométhyle, nitro, amino, phényle, benzyle, alkyle C1-C6, alcoxy C1-C6, alcanoylamino C2-C6, formylamino et alcoxy C1-C6-carbonyle, ou deux groupes adjacents de R-R4 forment conjointement un noyau benzène; les groupes restants étant hydrogène; R5 est hydrogène, alkyle C1-C6, un groupe benzyle ou phényle dans lequel la fraction phényle ou le cycle phényle est non substitué ou substitué par un ou deux substituants sélectionnés indépendamment parmi halogène, trifluorométhyle, alkyle C1-C6, alcoxy C1-C6, nitro, amino, hydroxy, formylamino, alcanoylamino C2-C6 et alcoxy C1-C6-carbonyle; R6 et R7, qui sont identiques ou différents, sont chacun indépendamment hydrogène ou un noyau phényle non substitué ou substitué par un ou deux substituants sélectionnés indépendamment parmi halogène, hydroxy, trifluorométhyle, nitro, amino, phényle, benzyle, alkyle C1-C6, alcoxy C1-C6, alcanoylamino C2-C6, formylamino et alcoxy C1-C6-carbonyle; ou bien R6 et R7 forment conjointement un système cyclique aromatique C6-C14 non substitué ou substitué par un ou deux substituants sélectionnés indépendamment parmi halogène, hydroxy, trifluorométhyle, nitro, amino, phényle, benzyle, alkyle C1-C6, alcoxy C1-C6, alcanoylamino C2-C6, formylamino et alcoxy C1-C6-carbonyle. L'invention se rapporte également à des sels pharmaceutiquement acceptables de ces composés qui présentent une activité inhibitrice dirigée contre l'enzyme kynurénine-3-hydroxylase.
EP98962319A 1997-11-27 1998-10-27 Composes benzenesulfamides Withdrawn EP1036069A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9725141 1997-11-27
GBGB9725141.7A GB9725141D0 (en) 1997-11-27 1997-11-27 Benzenesulfonamide compounds
PCT/EP1998/006994 WO1999028306A1 (fr) 1997-11-27 1998-10-27 Composes benzenesulfamides

Publications (1)

Publication Number Publication Date
EP1036069A1 true EP1036069A1 (fr) 2000-09-20

Family

ID=10822764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98962319A Withdrawn EP1036069A1 (fr) 1997-11-27 1998-10-27 Composes benzenesulfamides

Country Status (6)

Country Link
EP (1) EP1036069A1 (fr)
JP (1) JP2001524546A (fr)
AU (1) AU1753599A (fr)
CA (1) CA2309969A1 (fr)
GB (1) GB9725141D0 (fr)
WO (1) WO1999028306A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
EP2054397B1 (fr) * 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Inhibiteurs à petites molécules de kynurénine-3-monooxygénase
EP2420494B1 (fr) * 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Utilisation de composes derives de thiadiazoles comme inhibiteurs de la kynurenine-3- monooxygenase
MX2010000690A (es) 2007-07-18 2010-06-25 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8.
CA2747637A1 (fr) 2008-12-18 2010-07-15 Janssen Pharmaceutica Nv Sulfamides au titre de modulateurs de trpm8
WO2023049934A1 (fr) * 2021-09-27 2023-03-30 Board Of Trustees Of Michigan State University Composés pour traiter la maladie d'alzheimer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9928306A1 *

Also Published As

Publication number Publication date
JP2001524546A (ja) 2001-12-04
GB9725141D0 (en) 1998-01-28
CA2309969A1 (fr) 1999-06-10
AU1753599A (en) 1999-06-16
WO1999028306A1 (fr) 1999-06-10

Similar Documents

Publication Publication Date Title
US9718784B2 (en) Substituted pyrazoles as heat shock transcription factor activators
EP0283390B1 (fr) Dérivés du thiazole actifs sur le système cholinergique, procédé d'obtention et compositions pharmaceutiques en contenant
EP0934290B1 (fr) Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
WO1997000868A1 (fr) Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
EP1200419A1 (fr) Derives d'aminothiazole et leur utilisation comme ligands des recepteurs crf
EP1036069A1 (fr) Composes benzenesulfamides
WO1999028316A1 (fr) Composes thiophene-sulfamides
US6133302A (en) 5-(3-Phenyl-3-oxo-propyl)-1H-tetrazole derivatives
EP1054876A1 (fr) Derives de 1,2,3-thiadiazoles utilises comme inhibiteurs de kyn-oh
WO1999006375A1 (fr) Composes heterocycliques fondus et utilisation de ces composes comme inhibiteurs de la kynurenine-3-hydroxylase
US9255096B1 (en) Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
JP2001518473A (ja) 縮合ベンゾチオピラン化合物
CA2297096A1 (fr) Composes heterocycliques condenses
AU2011326130B9 (en) Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US9388181B2 (en) Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase
WO2024013690A1 (fr) Composés de 1,3,4-oxadiazole triazole utilisés en tant qu'inhibiteurs de l'histone désacétylase 6, et composition pharmaceutique les comprenant
EP1019380A2 (fr) Composes 3-oxo-propanenitrile tricycliques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000530;LT PAYMENT 20000530;LV PAYMENT 20000530;MK PAYMENT 20000530;RO PAYMENT 20000530;SI PAYMENT 20000530

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010223